Shorts On Watch: Time to Reconsider Tonix Pharmaceuticals (NASDAQ:TNXP) After More Short Sellers?

November 17, 2016 - By Darrin Black   ·   0 Comments

Shorts On Watch: Time to Reconsider Tonix Pharmaceuticals (NASDAQ:TNXP) After More Short Sellers?

The stock of Tonix Pharmaceuticals (NASDAQ:TNXP) registered an increase of 10.81% in short interest. TNXP’s total short interest was 828,400 shares in November as published by FINRA. Its up 10.81% from 747,600 shares, reported previously. With 2.43 million shares average volume, it will take short sellers 0 days to cover their TNXP’s short positions. The short interest to Tonix Pharmaceuticals’s float is 3.73%. About 311,465 shares traded hands. Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has declined 85.05% since April 15, 2016 and is downtrending. It has underperformed by 89.68% the S&P500.

TNXP Company Profile

Tonix Pharmaceuticals Holding Corp. (Tonix), incorporated on November 16, 2007, is a clinical-stage pharmaceutical company. The Company’s drug development programs are directed toward disorders affecting the central nervous system (CNS), and include fibromyalgia (FM), and post-traumatic stress disorder (PTSD). The Firm is focused on developing a portfolio of product candidates, including one product candidate in clinical development for registration in two indications.

Another recent and important Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) news was published by Businessfinancenews.com which published an article titled: “Tonix Pharmaceuticals Holding Corp Ready to Clinch Share From PTSD Market” on June 02, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Darrin Black


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>